Johnson & Johnson reported a 6% increase in worldwide sales for the fiscal year 2025, reaching $94.2 billion, compared to $88.8 billion in 2024. The company's net earnings from continuing operations were $26.8 billion, translating to earnings per share of $11.03, a significant rise from $5.79 in the previous year. This growth was driven by strong performance in both the Innovative Medicine and MedTech segments, with the Innovative Medicine segment generating $60.4 billion in sales, up 6% from the prior year, and the MedTech segment achieving $33.8 billion, also reflecting a 6.1% increase.
The company experienced notable changes in its product lines, particularly in the Innovative Medicine segment, where sales of oncology products surged by 22.1%, largely due to strong performances from DARZALEX and CARVYKTI. However, sales of STELARA declined by 41.3% due to increased competition from biosimilars. In the MedTech segment, the cardiovascular franchise saw a 15.8% increase in sales, bolstered by the acquisition of Shockwave Medical, which contributed positively to the segment's growth.
Strategically, Johnson & Johnson announced its intention to separate its Orthopaedics business in October 2025, with a targeted completion within 18 to 24 months. This decision is part of a broader strategy to streamline operations and focus on core areas of growth. The company also made significant acquisitions, including Intra-Cellular Therapies for $14.5 billion, which is expected to enhance its portfolio in mental health treatments.
Operationally, Johnson & Johnson employed approximately 138,200 individuals globally as of December 28, 2025. The company reported a 5.8% voluntary turnover rate, indicating a stable workforce. The company’s international sales accounted for approximately 43% of total sales, with Europe being a significant market. The company also faced challenges, including pricing pressures and regulatory scrutiny, particularly related to the Inflation Reduction Act, which may impact future sales and pricing strategies.
Looking ahead, Johnson & Johnson anticipates continued growth driven by innovation and strategic acquisitions, although it remains cautious about potential market challenges, including competition and regulatory changes. The company is committed to investing in research and development, with $14.7 billion allocated in 2025, reflecting its focus on delivering innovative healthcare solutions.
About JOHNSON & JOHNSON
Johnson & Johnson is a global healthcare company focused on human health and well-being. It develops, manufactures, and sells pharmaceuticals, medical devices, and consumer health products across various segments including Innovative Medicine and MedTech. Serving markets worldwide, it offers key products in immunology, oncology, cardiology, orthopedics, and vision, leveraging innovation, strong intellectual property, and a broad distribution network to maintain a competitive edge.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.